

USSN 08/870,762  
Attry Docket No. 18528.231/226/104

### REMARKS

A response to the July 29, 2005 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures was submitted to the Office on September 29, 2005. Among other items included the September 29, 2005 submission, Applicants submitted: a substitute sequence listing in computer readable form (CRF) on compact disc, a substitute sequence listing on compact disc (2 identical copies), a Compact Disk Transmittal Letter under 37 CFR §1.52(e), and a Statement under 37 CFR §1.821(f). However, Applicants inadvertently did not include a substitute paper copy of the sequence listing, and statements that the substitute sheets include no new matter and that the copy in the CFR is the same as the substitute paper copy. Applicants thank Examiner Devi for bringing this to our attention so that this matter could be rectified.

This substitute sequence listing was submitted because the specification included recitation of amino acid sequences that were not identified with a SEQ ID number in the previous sequence listing. In the September 29, 2005 submission, portions of the specification were amended to insert the SEQ ID NO identifiers associated with the sequences listed in the accompanying substitute sequence listing.

Submitted herewith is a substitute paper copy of the sequence listing. In accordance with 37 C.F.R. §1.821(f), this substitute paper copy is identical to the substitute sequence listing recorded in computer readable form (CRF) on compact disc, submitted on September 29, 2005. This substitute paper copy of the sequence listing, filed in accordance with 37 C.F.R. §1.821(g) and §1.825(a), does not include new matter.

Claims 1-16 are pending. By this amendment, claim 7 has been amended without prejudice or disclaimer of any previously claimed subject matter. Support for the amendment can be found, *inter alia*, throughout the specification and the claims as originally filed. No new matter has been added by this amendment.

The amendment is made solely to promote prosecution without prejudice or disclaimer of any previously claimed subject matter. With respect to all amendments and cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter and moreover, have not acquiesced to any rejections or objections made by the Patent Office. Applicants expressly

USSN 08/870,762  
Atty Docket No. 18528.231/226/104

reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).


Applicants respectfully request entry of this submission and believe that the present application is now in condition for allowance. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: March 14, 2006

By:   
Karen R. Zachow, Ph.D.  
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936